Leap Therapeutics reports updated results from Phase B of DeFianCe study

Leap Therapeutics (LPTX) reported updated results from Part B of the DeFianCe study, a Phase 2 study of sirexatamab, DKN-01, an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy compared to bevacizumab and chemotherapy in patients with advanced microsatellite stable, MSS, colorectal cancer, CRC, who have received one prior systemic therapy for advanced disease. Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naive and liver metastasis subgroups. “Sirexatamab demonstrated a statistically significant benefit in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis, with a positive trend on ORR and PFS in the full second-line CRC population. With the additional patient follow-up, we believe that the objectives of the DeFianCe study have been achieved,” said Douglas E. Onsi, President and Chief Executive Officer of Leap.